JP6983069B2 - 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法 - Google Patents

成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法 Download PDF

Info

Publication number
JP6983069B2
JP6983069B2 JP2017539525A JP2017539525A JP6983069B2 JP 6983069 B2 JP6983069 B2 JP 6983069B2 JP 2017539525 A JP2017539525 A JP 2017539525A JP 2017539525 A JP2017539525 A JP 2017539525A JP 6983069 B2 JP6983069 B2 JP 6983069B2
Authority
JP
Japan
Prior art keywords
igf
neural stem
cells
stem cells
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017539525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532068A (ja
JP2017532068A5 (cg-RX-API-DMAC7.html
Inventor
トーマス ヘイゼル，
カール ケー． ジョヘ，
Original Assignee
ニューラルステム， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ニューラルステム， インコーポレイテッド filed Critical ニューラルステム， インコーポレイテッド
Publication of JP2017532068A publication Critical patent/JP2017532068A/ja
Publication of JP2017532068A5 publication Critical patent/JP2017532068A5/ja
Application granted granted Critical
Publication of JP6983069B2 publication Critical patent/JP6983069B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
JP2017539525A 2014-10-20 2015-10-19 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法 Active JP6983069B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462066174P 2014-10-20 2014-10-20
US62/066,174 2014-10-20
US201562147950P 2015-04-15 2015-04-15
US62/147,950 2015-04-15
PCT/US2015/056226 WO2016064737A1 (en) 2014-10-20 2015-10-19 Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020201316A Division JP2021045156A (ja) 2014-10-20 2020-12-03 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法

Publications (3)

Publication Number Publication Date
JP2017532068A JP2017532068A (ja) 2017-11-02
JP2017532068A5 JP2017532068A5 (cg-RX-API-DMAC7.html) 2018-10-11
JP6983069B2 true JP6983069B2 (ja) 2021-12-17

Family

ID=55761367

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017539525A Active JP6983069B2 (ja) 2014-10-20 2015-10-19 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法
JP2020201316A Pending JP2021045156A (ja) 2014-10-20 2020-12-03 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020201316A Pending JP2021045156A (ja) 2014-10-20 2020-12-03 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法

Country Status (9)

Country Link
US (2) US9750769B2 (cg-RX-API-DMAC7.html)
EP (1) EP3209306B1 (cg-RX-API-DMAC7.html)
JP (2) JP6983069B2 (cg-RX-API-DMAC7.html)
KR (2) KR20190060016A (cg-RX-API-DMAC7.html)
CN (1) CN107148275A (cg-RX-API-DMAC7.html)
AU (2) AU2015336194B2 (cg-RX-API-DMAC7.html)
CA (1) CA2964927C (cg-RX-API-DMAC7.html)
MX (1) MX382488B (cg-RX-API-DMAC7.html)
WO (1) WO2016064737A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250022877A (ko) * 2017-01-31 2025-02-17 리젠엑스바이오 인크. 완전히-인간 글리코실화된 인간 알파-l-이두로니다아제(idua)를 이용한 뮤코다당증 1형의 치료
KR102245539B1 (ko) 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
WO2019165306A1 (en) * 2018-02-23 2019-08-29 Regeneration Biomedical, Inc. Methods, apparatuses and systems for instilling stem cells and pharmaceuticals into the human ventricular system
CN112469732A (zh) * 2018-07-17 2021-03-09 赫利世弥斯株式会社 使用胰岛素样生长因子1-加密脱氧核糖核酸构建体及肝细胞生长因子-加密脱氧核糖核酸构建体的神经病变治疗
EP3823981A4 (en) * 2018-07-17 2022-04-06 Neuromyon Inc. TREATMENT OF NEUROPATHY WITH DNA CONSTRUCTS EXPRESSING IGF-1 ISOFORMS
EP3852771A4 (en) 2018-09-19 2022-06-08 Regeneration Biomedical, Inc. WNT-ACTIVATED ADI-DERIVED STEM CELL DEVICES, METHODS AND SYSTEMS
KR20210077634A (ko) * 2019-12-17 2021-06-25 코아스템(주) 인간 만능 줄기세포로부터 3d 오가노이드를 이용하여 미세교세포를 다량 확보하는 미세교세포의 분화방법
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
WO2023158214A1 (ko) * 2022-02-15 2023-08-24 주식회사 헬릭스미스 인슐린-유사 성장인자-1의 이형체를 이용한 근감소증 예방 또는 치료용 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233838A3 (en) 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neurite-promoting factor and process for the manufacture thereof
US4753635A (en) 1986-05-23 1988-06-28 Jacqueline Sagen Inducing analgesia by implantation of cells releasing neuroactive substances
NZ226750A (en) 1987-10-29 1990-09-26 Amrad Corp Ltd Immortalisation of neural precursor cells by introducing a retrovirus vector containing a myc-oncogene
AU623922B2 (en) 1988-08-04 1992-05-28 Amrad Operations Pty. Limited In vitro propagation of embryonic stem cells
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US4980174A (en) 1988-12-23 1990-12-25 Jacqueline Sagen Method for alleviating depression
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
AU6174490A (en) 1989-08-04 1991-03-11 Board Of Regents, The University Of Texas System Methods and compositions; purified preparation of neural progenitor regulatory factor
WO1991009936A1 (en) 1989-12-26 1991-07-11 Hana Biologics, Inc. Proliferated neuron progenitor cell product and process
US5411883A (en) 1989-12-26 1995-05-02 Somatix Therapy Corporation Proliferated neuron progenitor cell product and process
US5196315A (en) 1990-05-01 1993-03-23 The Johns Hopkins University Human neuronal cell line
US5612211A (en) 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
US6294346B1 (en) 1991-07-08 2001-09-25 Neurospheres Holdings, Ltd. Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
DK0594669T4 (da) 1991-07-08 2008-04-21 Neurospheres Holdings Ltd Neurale progenitorceller, som reagerer på vækstfaktorer og kan formeres in vitro
US5851832A (en) 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5981165A (en) 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US7361505B1 (en) 1991-07-08 2008-04-22 Neurospheres Holdings Ltd. Multipotent neural stem cell compositions
US6497872B1 (en) 1991-07-08 2002-12-24 Neurospheres Holdings Ltd. Neural transplantation using proliferated multipotent neural stem cells and their progeny
US6399369B1 (en) 1991-07-08 2002-06-04 Neurospheres Holdings Ltd. Multipotent neural stem cell cDNA libraries
US6071889A (en) 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5175103A (en) 1991-10-21 1992-12-29 Trustees Of University Of Pennsylvania Preparation of pure cultures of post-mitotic human neurons
EP0625050B1 (en) 1991-11-22 1999-04-14 Genentech, Inc. Tgf-beta to improve neural outcome
US5672499A (en) 1992-07-27 1997-09-30 California Institute Of Technology Immoralized neural crest stem cells and methods of making
NZ256154A (en) 1992-07-27 1997-02-24 California Inst Of Techn Production of mammalian multipotent neural stem cells, antibodies
US5589376A (en) 1992-07-27 1996-12-31 California Institute Of Technology Mammalian neural crest stem cells
US5849553A (en) 1992-07-27 1998-12-15 California Institute Of Technology Mammalian multipotent neural stem cells
AU4995193A (en) 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
WO1994004675A2 (en) 1992-08-19 1994-03-03 Richard Kroczek Dna sequence encoding a novel member of the steroid and thyroid hormone receptor family
KR950704476A (ko) 1992-10-28 1995-11-20 브렌드 레이놀즈 생물학적 인자 및 신경 간세포(biological factors and neural stem cells)
CN1141058A (zh) 1993-11-09 1997-01-22 纽罗斯菲里斯控股有限公司 中枢神经系统干细胞的原位修饰和处理
ES2167461T3 (es) 1994-09-23 2002-05-16 Neurospheres Holdings Ltd Modelos in vitro de funcion y disfuncion del sistema nervioso central.
FI971956L (fi) 1994-11-14 1997-07-04 Neurospheres Holdings Ltd Hermosolujen lisääntymisen säännöstely
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5753505A (en) 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
US5770414A (en) 1996-02-20 1998-06-23 The Regents Of The University Of California Regulatable retrovirus system for genetic modification of cells
US5753506A (en) 1996-05-23 1998-05-19 Cns Stem Cell Technology, Inc. Isolation propagation and directed differentiation of stem cells from embryonic and adult central nervous system of mammals
US7544511B2 (en) 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
WO1998048001A1 (en) 1997-04-24 1998-10-29 California Institute Of Technology Methods for differentiating neural stem cells
JP4371179B2 (ja) 1997-07-04 2009-11-25 ユニバーシティー オブ ユタ リサーチ ファンデーション 系列限定ニューロン前駆体
US5968829A (en) 1997-09-05 1999-10-19 Cytotherapeutics, Inc. Human CNS neural stem cells
US5932473A (en) 1997-09-30 1999-08-03 Becton Dickinson And Company Preparation of a cell culture substrate coated with poly-D-lysine
US5958767A (en) 1998-08-14 1999-09-28 The Children's Medical Center Corp. Engraftable human neural stem cells
AU755849B2 (en) 1998-09-22 2002-12-19 Neuralstem Biopharmaceuticals, Ltd. Stable neural stem cell lines
US6284539B1 (en) 1998-10-09 2001-09-04 Neuralstem Biopharmaceuticals, Ltd. Method for generating dopaminergic cells derived from neural precursors
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
US7250294B2 (en) * 2000-05-17 2007-07-31 Geron Corporation Screening small molecule drugs using neural cells differentiated from human embryonic stem cells
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
CA2444214A1 (en) 2001-04-23 2002-10-31 The Trustees Of The University Of Pennsylvania Amyloid plaque aggregation inhibitors and diagnostic imaging agents
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
PT1590467E (pt) * 2003-01-28 2010-01-05 Hoffmann La Roche Utilização de sequências reguladoras para expressão específica transiente em células determinadas neuronais
CA2539947A1 (en) * 2003-09-24 2005-04-07 The Board Of Trustees Of The Leland Stanford Junior University Igf-1 instructs multipotent adult cns neural stem cells to an oligodendroglial lineage
EP1814979B1 (en) 2004-11-17 2015-04-08 Neuralstem, Inc. Transplantation of human neural cells for treatment of neurodegenerative conditions
US7833513B2 (en) * 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
AU2007217016A1 (en) * 2006-02-21 2007-08-30 Jeffrey Schwartz High-yield activation of polymer surfaces for covalent attachment of molecules
MX2010003371A (es) * 2007-09-28 2010-05-05 Intrexon Corp Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos.
WO2010018996A2 (ko) * 2008-08-12 2010-02-18 연세대학교 산학협력단 인간 신경줄기세포 및 이를 이용한 중추 또는 말초 신경계 질환 및 손상 치료용 약학적 조성물
US9657329B2 (en) * 2011-11-07 2017-05-23 The Broad Institute Inc. Propeptide-luciferase fusion proteins and methods of use thereof
CN102604894B (zh) * 2012-02-29 2014-07-30 中国科学院广州生物医药与健康研究院 用于制备神经干细胞的培养基及其用途
WO2014138003A1 (en) * 2013-03-04 2014-09-12 Neuralstem, Inc. Compositions comprising an immunosuppressive drug and/or neural stem cells and methods of using same for the treatment of neurodegenerative diseases and/or disorders

Also Published As

Publication number Publication date
MX2017005186A (es) 2017-07-26
EP3209306A1 (en) 2017-08-30
CA2964927C (en) 2019-07-30
CA2964927A1 (en) 2016-04-28
MX382488B (es) 2025-03-13
KR20190060016A (ko) 2019-05-31
EP3209306A4 (en) 2018-07-04
AU2015336194B2 (en) 2019-01-03
US20170319625A1 (en) 2017-11-09
AU2015336194A1 (en) 2017-05-04
US20160120942A1 (en) 2016-05-05
CN107148275A (zh) 2017-09-08
JP2017532068A (ja) 2017-11-02
AU2018279014A1 (en) 2019-01-17
US10702555B2 (en) 2020-07-07
KR20170067884A (ko) 2017-06-16
EP3209306B1 (en) 2024-04-24
US9750769B2 (en) 2017-09-05
KR102100021B1 (ko) 2020-04-13
WO2016064737A1 (en) 2016-04-28
JP2021045156A (ja) 2021-03-25

Similar Documents

Publication Publication Date Title
JP6983069B2 (ja) 成長因子をコードする外因性ポリヌクレオチドを含む安定な神経幹細胞およびその使用の方法
JP7566808B2 (ja) 神経変性を治療するための方法及び組成物
US8168169B2 (en) Methods and compositions for the treatment of medical disorders
US20190099452A1 (en) Methods for promoting oligodendrocyte regeneration and remyelination
US8481499B2 (en) Blockade of gamma-secretase activity to promote myelination by oligodendrocytes
JP2007530001A (ja) 希突起膠細胞前駆細胞ならびに希突起膠細胞前駆細胞を得るための方法および培養するための方法
KR20190051837A (ko) 중뇌 유래의 성상교세포와 도파민 신경줄기세포의 공동 이식에 의한 도파민 신경세포의 이식 치료 효과 개선
KR101544398B1 (ko) ＦｏｘＡ2 및 Ｎｕｒｒ1 도입을 이용한 중뇌 도파민성 신경세포로의 분화방법
AU2005313020A1 (en) Materials and methods related to Dickkopfs (DKK) and Neurogenesis
US20200181569A1 (en) Expandable cell populations from brain biopsies of living subjects
US20080213232A1 (en) Radial Glial Cells Promote Nerve Regeneration and Functional Recovery Following Spinal Cord Injury
Spencer et al. Systemic CNS Delivery of NPY for Alzheimer’s Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190805

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211027

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211122

R150 Certificate of patent or registration of utility model

Ref document number: 6983069

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250